Objectives: Follicle stimulating hormone (FSH) and its receptor (FSHR) disequilibrium, D‫׳‬ =0.182 and 0.1, r2 = 0.553 and 0.333 
INTRODUCTION
Ovarian cancer contributes to the highest mortality among all gynecological cancers and difference in incidence of ovarian cancer in different ethnic groups was reported 1 . The risk of ovarian cancer increases from the age of 35 and decreases after the age of 59
2
. The probability that a woman will be diagnosed with ovarian cancer before the age of 80 years is estimated at 1.5%
3 . The majority of ovarian cancer cases are sporadic. Familial cancer (about 10%) may develop due to inherited mutations of highly Penetrant BRCA1 and BRCA2 genes. 4 Much more common are low-penetrance genes that may account for a larger proportion of ovarian cancers in the general population 5 . Unfortunately, both high-and low-penetrance genes are difficult to identify.
The most well-known hypotheses of ovarian cancers development is the incessant ovulation hypothesis that promote cellular proliferation and genetic instability, the gonadotropin hypothesis with direct involvement of endogenous hormones 6 and the androgen hypothesis 7 , which postulates that ovarian cancer risk is enhanced by excessive androgen stimulation, while it is decreased by progesterone stimulation. Conditions associated with increase the number of ovulation such as pregnancy, oral contraceptive use and breastfeeding would significantly elevate the risk of developing ovarian cancer 8 . Ovulation was implicated as a risk factor for ovarian cancer 9 . Follicle-stimulating hormone (FSH) is essential for development of ovarian follicular. FSH evokes its biological effects by interacting with high affinity receptor located on the plasma membrane of its target cells in the gonads. The FSH and the FSH receptor (FSHR) expression levels were found to be significantly higher in the peritoneal fluids of the ovarian cancer patients 10 . It is thus likely that both ligand and receptor play a vital role in ovarian epithelial cancer development in a synergistic manner. Twenty randomly selected control subjects were included in this study. They had undergone salpingoophorectomy for benign conditions and all had exclusion criteria from ovarian carcinoma. The paraffin embedded tissues were retrieved from the Department of Pathology, Zagazig University.
SUBJECTS & METHODS

Extraction of DNA:
Dissection was performed to the tissue and prepared for DNA extraction after deparaffinization. After delivering tissues from Pathology Department, tissues were carved with surgical blade into 1 mm pieces and between 25 and 75 mg of each paraffin embedded tissue block was transferred to a microtube. Genomic DNA was then extracted from the deparafinized tissue using the conventional phenol/ chloroform method following the proteinase K digestion 16 . Equal volume of trissaturated phenol (pH=8) was added to the tubes and centrifuged at 12000 rpm for 2 min. 300 µl was transferred to equal volume of phenolchloroform mixture (1:1) and after centrifugation 2.5 volume of ethanol was added for DNA precipitation.
The DNA pellet was washed gently with 70% ethanol and then the pellet was dried and dissolved in 70 µl distilled water to be ready for PCR run.
Genotyping:
The . The primers used for Ala307Thr were as follows: forward 5`-GCT CTG AGC TTC ATC CAA TTT G-3`and reverse 5`-CTC TGC TGT AGC TGG ACT CAT T-3`, and for Ser680Asn :forward 5`-CCC AAA TTT ATA GGA CAG-3` and reverse 5`-GAG GGACAA GTA TGT AAG TG-3`. The PCR was carried out in 20 µl containing 1x PCR buffer, 3 mM MgCl2, 200 mM dNTP and 0.6 U of AmpliTaq polymerase (HoffmanLaRoche, Branchburg, NJ) ,and 300nM each forward and reverse primers.
After heating and denaturation for 5 min at 95°C for 5 min, the PCR was performed for 40 cycles of 20 sec at 95°C, 1 min at 55°C (for Ala307Thr) or 50 °C (for Ser680Asn) for 30 sec, and 72°C for 30 sec with final extension of 72°C for 5 min in a thermal cycler (a Perkin Elmer 4800 thermal cycler (PTC-100 machine, MJ Research, Inc., Watertown, Mass. USA).
The amplified PCR products (120 and 114 bp, respectively) were digested by restriction enzymes of AhdI (for SNP Ala307Thr) and BsrI (for SNP Ser680Asn) ( HoffmanLaRoche) at the optimized conditions for 18 h and then separated by 2.5 % polyacrylamide gel electrophoresis (Pharmacia Biotech by SEMKO AB, Sweden) using submarine chamber (Maxicell, EC 360 M-E-C apparatus Cooperation ST. Petersburg. Florida USA) including 5 mg/ml ethidium bromide. After electrophoresis, the gel was visualized under UV illuminator and the length of resulted fragments were detected using 100 Base-Pair Ladder (Bioron) was 0.2 mg/ml in 10 Mm Tris (pH 8.0), 1mM EDTA
. Statistical analysis:
All statistical tests were performed using the SPSS software (Version 11.0). Numerical data were expressed as Mean ±S D. Qualitative data were expressed as frequency and percentage. Chi-square (x 2 ) test was used to examine the relation between qualitative variables to evaluate the association of the FSHR genotypes in the diseased -control populations. Odds ratio (OR) and 95% confidence interval (CI) were used to measure the strength of the association. Histological subtypes, tumor stages and grades of the cancer, had also been analyzed independently for their risk association with the FSHR SNPs. Linkage disequilibrium (D‫)׳‬ analysis among the SNPs and the correlation coefficient, r 2 were analyzed between two SNPs. A probability value (p-value) less than 0.05 was considered significant. Table 2) .
RESULTS
This
The two FSHR SNPs were modestly in linkage disequilibrium (D‫)׳‬ in the cancer and control groups as D‫׳‬ = 0.182 and r 2 = 0.553, and D‫׳‬ = 0.1 and r 2 = 0.333, respectively (Table  3) .
Thr307-Asn680 and Ala307-Ser680 were the major haplotypes whereas Thr307-Ser680 and Ala307-Asn680 were the minor haplotypes in patients and controls ( 36 in their study focused on granulosa cell tumor, they studied the SNP Ser680Asn in seven mucinous cystadenocarcinoma and suggested the tendency for 680Ser carriers to have higher risk of developing this cancer.
Some SNPs in the FSHR promoter region were found to alter FSHR expression in vitro through changes in transcription factor binding sites although no correlation with basal FSH serum levels or ovarian response in women undergoing controlled ovarian stimulation for IVF treatment could be detected 37 . Gaber et al. 38 investigated the association between FSHR gene polymorphism at position 680 and the outcomes of controlled ovarian stimulation for in vitro fertilization (IVF) in Egyptian women. They stated that the homozygous Asn/Asn genotype of FSHR polymorphism at position 680 may be associated with a reduced ovarian response to controlled ovarian hyper-stimulation for IVF. 27 suggested that FSHR Ala/Ala genotype at position 307 may diminish chances of cancer recurrence in patients treated with taxane-platinum agents, while two serines at position 680 of the FSHR protein may increase the risk of recurrence and death.
In previous studies done by Sudo et al. 19 reported that the haplotype 307Ala-680Ser had significantly higher basal level of serum FSH, which might enhance proliferation and malignant transformation of the ovarian epithelium and thus contributed to the higher risk of ovarian cancer. This was concurred with our findings regarding risk association with the 307Ala and 680Ser carriers and the haplotype 307Ala-680Ser.
In opposite, Heubner et al.
40
could not find any association between FSHR Polymorphisms and ovarian cancer risk. 
